Tramadol
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Tramadol: From Pain Management to Juvenile Idiopathic Arthritis
One-Sentence Summary
Tramadol is a centrally-acting opioid analgesic (mu-opioid agonist with SNRI activity), currently used for moderate-to-severe pain. Among 10 TxGNN-predicted new indications, most are extremely high-scoring but mechanistically implausible rare genetic disorders flagged in this evidence pack as likely knowledge-graph noise. The only candidate with any literature support is Juvenile Idiopathic Arthritis (JIA), backed by 0 clinical trials and 2 indirectly related publications — a hypothesis-generating signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain management (opioid analgesic; moderate-to-severe pain) |
| Predicted New Indication | Juvenile Idiopathic Arthritis (JIA) |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Tramadol is a mu-opioid receptor agonist combined with serotonin/norepinephrine reuptake inhibition (SNRI-like activity), classified as a centrally-acting analgesic. Tramadol is already used off-label as an adjunct analgesic in adult inflammatory arthritis (OA/RA) pain control, so extending this to pediatric JIA for pain management has an indirect mechanistic rationale — inflammatory joint pain is, in principle, a target for opioid/SNRI-class analgesia. However, no literature or trial in this evidence pack directly evaluates tramadol in JIA patients; the two retrieved publications concern a different analgesic (ketoprofen) and a sickle-cell/JRA case report, not tramadol itself.
It is worth noting that 8 of the 10 TxGNN-predicted indications in this evidence pack (e.g., acromesomelic dysplasia, brachyolmia, myosclerosis, pseudoachondroplasia, rheumatoid nodulosis) are rare monogenic or structural skeletal/connective-tissue disorders with no plausible mechanistic link to opioid/SNRI pharmacology and zero supporting trials or literature. The evidence pack itself characterizes these as likely artifacts of sparse knowledge-graph nodes rather than genuine repurposing signals. JIA and RF-positive polyarticular JIA are the only two candidates reaching evidence level L4, and both are explicitly scored as “Research Question” rather than a viable Go candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20799760 | 2010 | PK/Efficacy study (different NSAID, not tramadol) | Paediatric Drugs | Reviews ketoprofen PK/efficacy in pediatric inflammatory/musculoskeletal pain; not tramadol-specific, cited for pediatric central analgesic context only |
| 12180751 | 2002 | Case report | The Journal of Rheumatology | Two cases of coexistent sickle cell disease and JRA with delayed diagnosis; does not evaluate tramadol |
Note: Neither publication directly studies tramadol in a JIA population — both are indirect/contextual references (tier 3 classification per the evidence pack).
India Market Information
Tramadol is currently not marketed in India per available registration data (0 licenses on record). No product authorization details are available to summarize.
Safety Considerations
- Drug Interactions: 321 total interactions identified via DDInter. Notable Major-level interactions include: Alvimopan, Bupropion, Cisapride, Dexfenfluramine, Diethylpropion, Dolasetron, Dronabinol, Ephedrine, Fenfluramine. Notable Moderate-level interactions include: Atropine, Bisacodyl, Castor oil, Cimetidine, Clarithromycin, Clidinium, Dicyclomine, Eliglustat, Eluxadoline, Famotidine, Glycerin. Given tramadol’s SNRI-like activity, particular attention to serotonergic co-medications (e.g., dronabinol, dexfenfluramine, fenfluramine) is warranted for serotonin syndrome risk.
Official warnings and contraindications data are not yet available for this drug (see Next Steps below).
Conclusion and Next Steps
Decision: Hold
Rationale: Most TxGNN-predicted indications for tramadol lack any mechanistic or empirical support and are assessed as likely graph-prediction noise; even the best-supported candidate (JIA) has only indirect, non-tramadol-specific literature and no clinical trials. Combined with tramadol’s non-marketed status in India and a blocking data gap on official label warnings/contraindications, the evidence does not support progression beyond a research hypothesis at this stage.
To proceed, the following is needed:
- India-specific product label warnings and contraindications (currently blocking — required before any S1 safety screening)
- Confirmed mechanism-of-action documentation from DrugBank (currently a data gap)
- Tramadol-specific pediatric/JIA clinical or pharmacokinetic studies
- Full review of the 321 catalogued drug interactions, prioritizing serotonergic and opioid-potentiating agents, before any safety monitoring plan is drafted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.